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Abstract: We here report an experimentally verified binding mode for the known 
tripeptidomimetic CXCR4 antagonist KRH-1636 (1). A limited SAR study was first conducted 
based on the three functionalities of 1, followed by site-directed mutagenesis studies. The 
receptor mapping showed that both the potency and affinity of 1 were dependent on the 
transmembrane residues His113, Asp171, Asp262, and His281, and also suggested the involvement of 
Tyr45 and Gln200 (potency) and Tyr116 and Glu288 (affinity). Molecular docking of 1 to an X-ray 
structure of CXCR4 showed that the L-Arg guanidino group of 1 forms polar interactions with 
His113 and Asp171, the (pyridin-2-ylmethyl)amino moiety is anchored by Asp262 and His281, while 
the naphthalene ring is tightly packed in a hydrophobic subpocket formed by the aromatic side 
chains of Trp94, Tyr45, and Tyr116. The detailed picture of ligand-receptor interactions provided 
here will assist in structure-based design and further development of small-molecule 
peptidomimetic CXCR4 antagonists. 
 
INTRODUCTION 
Chemokines are small (8-14 kDa) proteins from the cytokine superfamily that exert their 
biological effects through interaction with GPCRs.1 The involvement and physiological role of 
the chemokine ligand-receptor system extends from control of chemotaxis (directional migration 
of leukocytes)2 and hematopoiesis3 to embryonic development, angiogenesis and cancer 
metastasis.4, 5 The human CXC chemokine receptor 4 (CXCR4) is activated by CXC chemokine 
ligand 12 (CXCL12), which is a 68-residue polypeptide.6, 7 The CXCL12:CXCR4 interaction is 
involved in development of the hematopoietic, nervous, and gastrointestinal systems8, 9 and plays 
an essential role in immune defense and inflammation.10, 11 In addition to these physiological 
roles, CXCR4 is the co-receptor for cellular entry of T-tropic HIV strains;12, 13 thus, inhibition of 
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CXCR4 has emerged as a promising strategy for anti-HIV therapy. CXCR4 has also been shown 
to play an important role in angiogenesis, metastasis and stem-cell mobilization.2, 4 Consequently, 
development of CXCR4 antagonists for therapeutic applications remains an important goal.  
Significant advances in the development of novel CXCR4 antagonists have been made and 
several different classes of CXCR4 antagonists, both peptides and non-peptides, have been 
reported.14-16 So far, the hematopoietic stem cell mobilizing agent plerixafor (AMD3100, Figure 
1A)17 is the only CXCR4 antagonist that has reached the market.18 Due to its high positive charge 
at physiological pH, AMD3100 exhibits poor oral bioavailability, and is therefore administered 
by subcutaneous injection.  
Extensive studies by Fujii and co-workers on polyphemusin II-derived peptide CXCR4 
antagonists culminated in the discovery of the potent cyclopentapeptide antagonist FC131 
(Figure 1B).19 Successive SAR studies of FC131 have since shown that the Arg1-Arg2-2-Nal3 
tripeptide fragment of the cyclopentapeptide serves as an essential recognition motif for peptide-
based CXCR4 antagonists,20-24 providing impetus for development of tripeptidomimetic ligands 
that block CXCR4. Indeed, a series of tripeptide-like CXCR4 antagonists containing a central 
arginine residue has been reported by Kureha Chemical Industries25-27 with the potent 
tripeptidomimetic 1 (KRH-1636, Figure 1C)28, 29 as a prototype compound. These small-molecule 
peptidomimetics represent a particularly interesting class of CXCR4 antagonists due to their 
potentially improved pharmacokinetic properties compared to their peptide counterparts.30, 31 
Based on structural comparison of low-energy conformations of 1 with a 3D-pharmacophore 
model for the cyclopentapeptide CXCR4 antagonists, 1 has been suggested to mimic the Arg1-
Arg2-2-Nal3 fragment of FC131.32 However, it has not been shown experimentally that the two 




Figure 1. Structures of selected CXCR4 antagonists: (A) bicyclam AMD3100, (B) 
cyclopentapeptide FC131, (C) prototype arginine-based tripeptidomimetic 1, (D) 16-mer peptide 
2, (E) isothiourea derivative 3, and (F) tetrahydroquinoline derivative 4. 
The first X-ray structures of CXCR4 were reported in 2010, and are co-crystallized complexes 
containing the 16-mer peptide antagonist 2 (CVX15, Figure 1D) and the small-molecule 
antagonist 3 (IT1t, Figure 1E).33 Very recently, an X-ray structure of a covalent complex between 
CXCR4 and the viral chemokine vMIP-II was also released.34 The CXCR4:2 complex provided 
the first detailed insight into binding of a peptide antagonist to CXCR4, and based on this 
structure we have recently reported an experimentally verified binding mode for the 
cyclopentapeptide FC131 (Figure 1B).35 Prior to the publication of the X-ray structures of 
























































which resulted in the identification of plausible binding modes for the bicyclam AMD3100,36-38 
its monocyclam analogs,39, 40 and the non-cyclam 4 (AMD11070, Figure 1F).40 However, while 
the molecular pharmacology of the prototype small-molecule peptide and non-peptide CXCR4 
antagonists has been extensively characterized, experimental binding mode studies for the more 
drug-like tripeptidomimetic CXCR4 antagonists have not been reported. Thus, in order to 
facilitate rational design of novel peptidomimetic CXCR4 antagonists, we here report the 
binding mode of the known tripeptidomimetic CXCR4 antagonist 1 using a combination of SAR 
studies, receptor mapping by site-directed mutagenesis, and molecular docking. 
 
RESULTS AND DISCUSSION 
SAR Study. Design. The lead compound 1 was developed from a hit compound identified 
through screening of a chemical library,28, 29 and although recent patent literature discloses 
compounds related to 1,25-27 no SAR data has been reported for this compound class. In order to 
confirm the importance of the functionalities in 1 that could be assumed to represent 
pharmacophoric groups, we first carried out a limited SAR study focusing on the two positively 
charged groups (R1 and R2) and the aromatic group (R3) (Figure 2). In order to probe the R1 
position, the pyridine ring was replaced with a phenyl ring (5), the pyridin-2-ylmethyl substituent 
was removed to give the primary amine (6), and the charged (pyridin-2-ylmethyl)amino moiety 
was removed altogether (7). The importance of the charged guanidino group (R2) was 
investigated by replacing it with a urea group (8), while the aromatic position (R3) was probed by 




Figure 2. Structures of compounds 1 and 5–9; the modified groups (R1, R2, and R3) in the lead 
compound 1 are highlighted. 
Chemistry. Compounds 1 and 5–9 (Figure 2) were all prepared by adopting a procedure 
previously reported for the synthesis of 1 (Scheme 1).29 For compound 1, the right-hand side was 
prepared by N-alkylation of Boc-protected pyridin-2-ylmethanamine (10) with methyl 4-
(bromomethyl)benzoate followed by hydrolysis of the methyl ester to give carboxylic acid 11. 
The left-hand side was assembled by coupling of Fmoc-L-Arg(Pbf)-OH with (S)-1-(naphthalen-
1-yl)ethanamine using PyBOP as the coupling reagent, followed by Fmoc-deprotection with 
diethylamine in DMF to afford amine 12. Coupling of the two halves (11 and 12) was facilitated 
by EDCI/HOBt, and subsequent removal of the Boc and Pbf protecting groups by treatment with 
a TFA cocktail gave 1. For the preparation of 6 and 7, the left hand side (12) was coupled with 
N-Boc 4-(aminomethyl)benzoic acid and 4-methylbenzoic acid, respectively. Analog 5 was 
prepared by N-alkylation of 6 with benzyl bromide using K2CO3 as base and DMF as solvent. 
The R2 analog 8 was prepared using Fmoc-protected citrulline as the starting material while the 
















































Scheme 1. Synthesis of compound 1. 
 
Reagents and conditions: (a) i) NaH, DMF, 0 °C; ii) Methyl 4-(bromomethyl)benzoate, DMF, 
0 °C to rt; (b) 1M NaOH/THF/MeOH (1:1:1); (c) (S)-1-(naphthalen-1-yl)ethanamine, PyBOP, 
DIPEA, CH2Cl2 0 °C to rt.; (d) Et2HN, DMF; (e) 11, EDCI, HOBt, DMF; (f) TFA/TIS/H2O 
(95:2.5:2.5). 
 
Biology and SAR. The antagonistic potency of compounds 1 and 5–9 (Table 1) was assessed in 
a functional assay measuring the inhibition of CXCL12-induced activation of human CXCR4, 
transiently expressed in COS-7 cells. The known lead compound 1 was originally reported by 
Ichiyama et al. to efficiently inhibit binding of [125I]CXCL12 (IC50 = 0.013 µM),28 and our own 
functional data validates 1 as a potent CXCR4 antagonist (EC50 = 0.50 µM, Table 1) with respect 
to the endogenous ligand CXCL12. The phenyl-analog 5 (EC50= 8.5 µM) displayed 17-fold 
lower potency than 1, demonstrating an important role of the pyridine nitrogen in 1. The potency 
of the primary amine 6 (EC50= 12 µM) was 24-fold lower than for 1, representing the overall 































of potency for compound 7 (EC50 > 100 µM) confirms the positively charged amino-group in R1 
as an essential pharmacophoric element. Compound 8, containing a neutral urea group that partly 
retains the H-bonding properties of the original guanidino group, failed to show antagonistic 
potency (EC50 > 100 µM), demonstrating the importance of the positive charge in R2 position. 
Similarly, the loss of potency for the R3 analog 9 (EC50 > 100 µM) confirms an important role for 
the naphthyl group. 
 
Table 1. Antagonistic potency of 1 and 5–9 on human CXCR4. 
compd log EC50 ± SEMa EC50 (μM) 
1b -6.30 ± 0.07 0.50 
5 -5.12 ± 0.08 8.5 
6 -4.93 ± 0.08 12 
7  > -4 > 100 
8 > -4 > 100 
9 > -4 > 100 
aEC50 values represent the mean of at least three independent experiments performed in 
duplicates. bKnown compound. 
 
Earlier attempts to improve the pharmacokinetic profile of the bicyclam CXCR4 antagonists, 
i.e. AMD3100 (Figure 1A), led to the discovery of the monocyclam AMD3465 (Figure 3),41 
which was shown to be 22-fold more potent than its precursor AMD310039 and contains the same 
(pyridin-2-ylmethyl)amino moiety as 1. The importance of this group for the antagonistic 
activity of AMD3465 has been investigated previously using the analogs 13 (AMD3529) and 14 
(AMD3389) (Figure 3),39 which are structural counterparts of the KRH-analogs 5 and 7 in the 
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present study (Figure 2). In line with the present findings for 5 and 7 (Table 1), 13 and 14 were 
shown to display significantly lower potencies for CXCR4 than AMD3465 as determined by a 
functional assay inhibiting CXCL12-induced receptor activation.39 
 
 
Figure 3. Structures and reported potencies of the monocyclam AMD3465 and the two analogs 
13 and 14,39 also showing the structural analogy of these monocyclams with the R1 substituent in 
compounds 1, 5, and 7 in the present study. 
Regarding the central Arg residue in 1 (R2), it has been suggested that this position could 
correlate to Arg2 in the cyclopentapeptide antagonist FC131 (Figure 1).32 SAR studies of the 
cyclopentapeptides have shown that the Arg2 position is very sensitive to modifications,20, 23 and 
that replacement of the guanidino group with a urea group (Cit2) leads to complete loss of 
antagonistic potency,23 which is in agreement with the present data for the KRH-analog 8. 
Collectively, the findings from this initial SAR study confirmed that the secondary amine, the 
guanidino group, and the aromatic naphthyl group are essential for the antagonistic potency of 1, 
while the pyridine ring in R1 position contributes to increased potency. 
Identification of Binding Site for 1: Receptor Mutagenesis. Next, we carried out 
mutagenesis studies to map key binding interactions between 1 and CXCR4 using a library of 25 
CXCR4-mutants (Table 2). Most of the mutations were located in the transmembrane helices 


















TM5. In most cases, the mutations included replacement with Ala; however, certain acidic Asp 
residues were alternatively substituted with the structurally similar and uncharged Asn residue. 
Selective substitutions with Trp were also done in order to introduce more bulk. We have 
recently utilized the same receptor library to map the binding of the cyclopentapeptide CXCR4 
antagonist FC131, where we reported the surface expression (using ELISA) and functional 
response to CXCL12 of WT-CXCR4 and all mutant receptors35 (the same data is provided in 
Table 2). While there was some variation in surface expression and ability to be activated by 
CXCL12, the receptors in the mutant library were considered suitable for mapping of the binding 
site, as previously discussed.35 
Inhibition of CXCL12-induced Activation of CXCR4. We first assessed the antagonistic 
potency of 1 on the entire CXCR4 mutant library (Table 2). The H113A, D262N, and H281A 
mutations were found to have the largest impact (>25-fold reduction) on the antagonistic potency 
of 1 relative to WT-CXCR4 (the position of residues based on the generic numbering system 
proposed by Baldwin42 and modified by Schwartz43 followed by the Ballesteros/Weinstein 
numbering system44 is given in Tables 2 and 3). The potency of 1 was also reduced (by 5-25 
fold) by mutations of Tyr45 (Y45A), Asp171 (D171N), Gln200 (Q200A and Q200W), Trp252 
(W252A), Ile259 (I259A), and Ile284 (I284A). In contrast, the W94A, D97A, T117A, and F189A 
mutants led to increased potency (>2-fold). 
As the mutagenesis data for 1 alone did not provide information about which parts of the 
ligand that interact with the different parts of the receptor, the R1 analogs 5 and 6 (Figure 2), 
which showed decent activity on WT-CXCR4 (Table 1), were also included in the mutagenesis 
study to further probe the molecular interactions of the R1-side chain with CXCR4. The 
collective functional data analysis for 1, 5, and 6 (Table 2) showed that the mutations in TM1 
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(Y45A), TM2 (W94A, D97A), TM3 (H113A, T117A), TM4 (D171N), and ECL2 affected the 
three ligands in a similar manner. However, several mutations in TMs 5-7 affected the three 
ligands in a distinctive manner. Specifically, the H281A mutation in TM7 was the mutation with 
largest effect on the potency of 1 (61-fold reduction), but affected analog 5 to a much lesser 
extent (6-fold). Thus, the overall trend identified in the phosphatidylinositol (PI) turnover 
experiments for 1, 5, and 6 (Table 2) suggests that the structurally modified R1 group contacts 
TMs 5-7; this trend is further illustrated in Figure 4. 
The absolute majority of the mutations had no or little effect on the potency of CXCL12 (Table 
2), demonstrating that most of the mutants were functional. However, the W94A, D97A, and 
D187A mutations reduced the agonistic potency of CXCL12 by 8-14 fold (Table 2). 
Furthermore, the Y116A and E288A mutants were not activated by CXCL12 in spite of 
expression levels of 69 and 77%, respectively (Table 2); consequently, no data on the 
antagonistic action of 1, 5, and 6 on these mutants are available. In line with the findings in the 
present study, the D97A, D187A, and E288A mutations have previously been found to affect 
both the binding and signaling of CXCL12.37, 45-49 Moreover, Trp94 and Tyr116, together with the 
three aforementioned residues, have been implicated as part of “site two” in the “two-site model” 
for binding of CXCL12 to CXCR4.33, 45, 50, 51 Additionally, the direct interaction of Tyr116 with 
agonists has been suggested in activation of GPCRs.34, 52 Thus, for these residues there are certain 
limitations in using CXCL12 as a probe. 
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Table 2. Potency of the lead compound 1 and the R1-analogs 5 and 6 on WT-CXCR4 and 25 
mutant receptors, measured as inhibition of CXCL12-induced activation in COS-7 cells 
transiently co-transfected with CXCR4 receptor mutants and chimeric G protein Gqi4myr 
(functional assay). 
 
aData for CXCL12 activation are from ref. 35. bThe position of each residue is given based on 
the generic numbering system proposed by Baldwin and modified by Schwartz, followed by the 
Ballesteros/Weinstein numbering system. cFmut is the ratio of the mutant and WT-CXCR4 
potencies. Red: Fmut >25; orange: Fmut from 10-25; yellow: Fmut from 5-10; green: Fmut <0.5. EC50 
values >100 μM are underlined and also colored red. P<0.001***, P<0.01**, P<0.05*. dThe 
number of independent experiments is shown in parentheses (n). eThese mutant receptors were 




Figure 4. (A-C) Bar-graph representations of fold-reduction in potency (Fmut) for compounds 1, 
5, and 6 for each mutant with respect to WT-CXCR4 (functional data, Table 2). Grey bars: 
mutants in TMs 1-4 and ECL2; black bars: mutants in TMs 5-7. (D-F) Residues identified to be 
important for the potency of compounds 1, 5, and 6 (functional data, Table 2), shown in a helical 
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wheel diagram of CXCR4. Red background color: >25 fold decrease; orange: 10-25 fold 
decrease; yellow: 5-10 fold decrease. 
 
 
Figure 5. (A) Ability of the lead compound 1 and analogs 5 and 6 to inhibit CXCL12 induced 
activation of WT-CXCR4, and (B) to displace 125I-12G5 from WT-CXCR4. 
Displacement of Radiolabeled Monoclonal Antibody (125I-12G5). To address the issue of 
reduced activity of CXCL12 in certain mutants (W94A, D97A, Y116A, D187A, and E288A) a 
competitive binding assay using the radiolabeled monoclonal antibody 12G5 (125I-12G5) was 
employed to probe ligand affinity (Table 3). A good correlation between anti-HIV potency and 
binding affinity measured as displacement of 125I-12G5 has previously been demonstrated for the 
bicyclam antagonists,36, 38, 53 which represents an additional advantage of using 12G5 as 
radioligand. In addition to the five mutants mentioned above, the binding experiments were 
extended to also include four of the mutants that were identified as important for the potency of 1 
in the functional assay (H113A, D171N, D262N, and H281A). All nine mutants had similar 
affinities for 12G5 as the WT receptor (Table 3), meaning that the mutations did not significantly 
affect receptor folding.  
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Compared to the strong antagonistic potency (EC50 = 0.50 μM) measured in the functional 
assay (Figure 5A), 1 displayed lower affinity to WT-CXCR4 (IC50 = 8.0 μM) measured against 
125I-12G5 (Figure 5B), suggesting that this compound binds allosterically with respect to 12G5. 
This finding clearly illustrates the differences between displacing 125I-12G5 (Table 3) and 
inhibiting the action of CXCL12 (Tables 1 and 2). The two R1 analogs 5 and 6 did not 
completely displace 12G5 (Figure 5B) – which also indicates an allosteric binding mode – and 
were therefore excluded from further binding experiments. The affinity of 1 determined against 
125I-12G5 was strongly (8- to >12-fold) negatively affected by the TM3 mutants H113A, the 
TM4 mutant D171N, the TM5 mutant D262N, and the TM7 mutants H281A and E288A (Table 
3). Moreover, 1 could not displace 12G5 from the Y116A-mutant. Overall, the binding data 
show that His113, Tyr116, and Asp171 at the interface between TM3 and TM4, and Asp262, His281, 
and Glu288 at the interface between TM6 and TM7 in the main binding pocket are important for 
the displacement of 12G5 by 1.  
To summarize, the functional studies (Tables 1 and 2) and the binding studies (Table 3) show 
that Tyr45 (TM1), His113 and Tyr116 (TM3), Asp171 (TM4), Gln200 (TM5), Asp262 (TM6), and His281 
and Glu288 (TM7) are important for the function and/or binding of 1. 
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Table 3. Affinity of 1 for WT-CXCR4 and nine mutant receptors measured as displacement of 
125I-labeled antibody 12G5 in transiently transfected COS-7 cells (competition binding assay). 
 
aData for 12G5 binding are from ref. 35. bFmut is the ratio of the mutant and WT-CXCR4 
affinities. cThe number of independent experiments is shown in parentheses (n). dP<0.001***, 
P<0.01**, P<0.05*. eThe position of each residue is given based on the generic numbering 
system proposed by Baldwin and modified by Schwartz, followed by the Ballesteros/Weinstein 
numbering system. 
 
Molecular Docking and Derived Binding Model. Binding Model: Key Interactions. In order 
to rationalize the experimental data, 1 was docked to the X-ray structure of CXCR4 (PDB code 
3OE0)33 using Schrödinger’s induced-fit docking protocol,54 which models the conformational 
changes induced by ligand binding. In order to avoid generation of irrelevant poses, a H-bond 
constraint was set on His113 (Nδ1), which was shown to be highly important for both the affinity 
and potency of 1. Visual inspection of the 15 generated ligand-receptor complexes resulted in the 
identification of a pose that was in agreement with the experimental data. In our proposed 
binding model (Figure 6), the (pyridin-2-ylmethyl)amino moiety (R1 side chain) of 1 is oriented 
towards the TM6 and TM7 region, and the R1 side chain adopts a bent conformation around the 
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secondary amino group, where the pyridine and phenyl rings lie in almost parallel planes. His281 
in TM7 forms an aromatic π-π stacking interaction with the pyridine ring, and Asp262 in TM6 is 
involved in a bidentate interaction with the charged secondary amine in the R1 side chain of 1. 
The guanidino group of Arg (R2-position) forms polar interactions with His113 and Thr117 (TM3) 
and Asp171 (TM4). The aromatic naphthyl ring (R3-position) is embedded in a hydrophobic 
pocket formed by the aromatic side-chains of Tyr45 and Trp94, and further stabilized by the Tyr116 
side-chain located directly below Trp94. Interestingly, previous studies indicate that the three 
aromatic residues Tyr45, Trp94 and Tyr116 of CXCR4, which are also found in the CCR5 
chemokine receptor as Tyr37, Trp86, and Tyr108, respectively, might form a hydrophobic pocket 
that is involved in the binding of small-molecule inhibitors.55, 56 Thus, mutations of the 
aforementioned three residues could destabilize the hydrophobic subpocket that interacts with 
the naphthyl ring of 1. Furthermore, the observation that Tyr116 is involved in a direct interaction 
with Glu288 (see Supporting Information, Figure S1) implies that the Y116A mutation can affect 
the overall geometry of the main binding crevice, specifically the orientations of TM3 and TM7. 
Thus, the Y116A mutation may indirectly affect the potential interactions between the ligand and 
His113, Thr117, His281, and Glu288. 
Binding Model: Indirect Effects. The docking pose for 1 also reveals the involvement of Glu288, 
which is a key residue as shown in the binding assay (Table 3). A Glu residue at this position 
(VII:06/7.39) is highly conserved among chemokine receptors and acts as an anchor point for 
several small molecule ligands.57 Glu288 in CXCR4 has been consistently implicated in binding 
modes of several different classes of CXCR4 antagonists, i.e. AMD3100, AMD3465, 4, FC131, 
and also the CXCR4 co-crystallized ligands 2 and 3,33, 35, 37, 39, 40 either through direct or water-
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mediated interactions with the ligand. Similarly, our binding model shows a water-mediated 
interaction between Glu288 and the ligand backbone (Figure 6).  
Substitution of Gln200 with Ala and Trp (Q200A and Q200W) caused a 7- and 21-fold 
reduction in potency of 1 with respect to WT-CXCR4; the involvement of this residue was also 
seen in previous binding mode studies of the monocyclam antagonist AMD3465.39 In our 
binding model for 1 (Figure 6), an intra-receptor H-bond between Gln200 and Asp262 was 
identified, suggesting that substitution of Gln200 can affect the interaction between Asp262 and the 
ligand. 
The model further shows an interaction between the guanidino group of Arg188 and the ligand 
backbone (Figure 6), which was also previously identified in the binding modes of the peptide 
antagonists FC131 and 2.23, 33, 58 However, the R188A mutation did not have any effect on the 
antagonistic potency of 1 or the two analogs (Table 2); interestingly, the R188A-mutant was also 
reported to have no effect on the potency of FC131.35 A possible explanation is that both 1 and 
FC131 are doubly positively charged, which results in electrostatic repulsion by Arg188. 
Substitution of Arg188 with Ala (R188A) therefore results in two opposing effects: an unfavorable 
removal of the H-bond interaction with the ligand, and a favorable removal of the electrostatic 
repulsion. Thus, it can be hypothesized that the net result is no overall effect of the R188A 




Figure 6. (A) Effects of the H113A and D171N mutations on the inhibition of CXCL12-induced 
PI turnover by 1. (B) Proposed binding model for 1, showing the key interacting residues in 
CXCR4; the ligand is shown in orange sticks, the receptor in grey-white sticks and ribbons, and 
the water molecule as a red sphere; H-bonds are shown in magenta, and π-π interactions in 
green. (C) Effects of the H281A and D262N mutations on the inhibition of CXCL12-induced PI 
turnover by 1. (D) 2D-representation of the docking pose for 1. 
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While the effect of most mutations (Tables 2 and 3) can be explained by the binding model, it 
is not possible to rationalize every single one. For example, the W94A and D97A mutations both 
led to increased potencies for all three analogs (Table 2). Earlier studies have suggested the 
involvement of these residues in the second binding step (“site two”) for the endogenous ligand 
CXCL12,33, 45 and the present mutagenesis data showed a reduced ability (13-14 fold) of 
CXCL12 to induce signaling for the W94A and D97A mutants. Moreover, the X-ray structure of 
CXCR4 suggests that Asp97 constitutes a gate-entry position that controls ligand access to the 
major binding pocket;33, 35 thus, a pre-interaction with Asp97 is implicated in the passage of the 
ligands to the TM receptor region. Taken together, the existing data supported by our 
mutagenesis suggest that the TM2 residues (Trp94 and Asp97) have a less distinctive involvement 
in the binding of these ligands to the receptor. First, mutation of Trp94 and Asp97 will weaken the 
binding of CXCL12, thereby increasing the antagonistic potency of the three analogs as reflected 
in Table 2. Second, the potential pre-interaction with Asp97 is removed in the D97A mutant, 
which allows easier access of the ligands to the TM binding pocket. Third, the involvement of 
the Trp94 in the hydrophobic pocket surrounding the naphthalene ring (R3-position) in 1 (Figure 
6), suggests that removal of the bulky side chain of Trp (W94A-mutant) allows a more 
energetically favorable position of the naphthyl group in the binding pocket.  
Conversely, mutation of hydrophobic residues in TM6 and TM7 reduced the potency of 1 
(W252A, I259A and I284A) and 6 (W252A and I284A). However, residues Trp252, Ile259, and 
Ile284 are not directly involved in ligand binding, meaning that the observed effects of the 
mutations most likely are secondary, i.e. implemented through local or global changes in TM6 
and TM7. 
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Despite the lower WT potency of 6 (Table 2), the effects of mutants Y45A and D171N were 
more pronounced for this analog. Our SAR data showed that gradual removal of the R1 group led 
to reduced potency, while the receptor mapping (Table 2) suggested that the R1 group contacts 
TMs 5-7. It could be reasoned that the weakened interaction of 6 with TMs 5-7 (R1 group 
interaction) makes the remaining interactions more important, which would explain the stronger 
dependence on Tyr45 (R3 group interaction) and Asp171 (R2 group interaction) for 6 (Table 2).  
Comparison with Experimentally Determined Binding Modes for Other Small-molecule 
CXCR4 Antagonists. Isothiourea Derivatives. Gebhard et al. have reported a series of small-
molecule isothiourea derivatives that selectively block CXCL12 and HIV gp120 binding to 
CXCR4.59, 60 The X-ray structures of CXCR4 in complex with the most potent compound 3 
(Figure 1E)33 later showed that 3 exhibits a unique binding mode by occupying the so-called 
“minor binding pocket” between TMs 1, 2, 3, and 7,61 i.e. without interacting with TMs 4-6. 
Consequently, the binding mode of 3 differs from other reported binding modes of CXCR4 
antagonists (see below), and is distinct from the present binding mode for 1.  
Peptide Antagonists. Prior to the publication of the X-ray structure of CXCR4, computational 
binding mode studies had been performed for the cyclopentapeptide CXCR4 antagonist FC13162, 
63 and 163 based on molecular docking to homology models of CXCR4 that were built on the 
crystal structure of bovine rhodopsin. These studies were purely theoretical, i.e. not based on any 
experimentally verified ligand-receptor interactions. Moreover, when the X-ray structure of 
CXCR433 was revealed in 2010 it showed that bovine rhodopsin was a poor template for 
CXCR4,64 questioning the validity of the previously proposed binding models for the small 
molecule peptide-based antagonists.  
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However, we have recently proposed an experimentally verified binding mode for FC131 
based on ligand modifications, receptor mutagenesis, and molecular docking to the X-ray 
structure of CXCR4.35 The binding model for FC131 was generally consistent with the binding 
mode for the Arg1-Arg2-1-Nal3 fragment of the 16-mer peptide antagonist 2 in complex with 
CXCR4 (PDB code 3OE0),33 i.e. the Arg1 side-chain in FC131 projected towards ECL2 of the 
receptor to interact with Asp187, the Arg2 guanidino group interacted with His113, Thr117, and 
Asp171 in TMs 3-4, while the aromatic 2-Nal3 side-chain was accommodated in a hydrophobic 
pocket around TM5.  
Thus, the Arg2 guanidino group in FC131 and the guanidino group (R2 position) in 1 both 
interact with His113, Thr117, and Asp171 (Figure 6); structural comparison of the reported binding 
mode for FC13135 and the present binding mode for 1 (Supporting Information, Figure S2) also 
shows that the L-Arg2 side chain of FC131 overlaps relatively well with the central arginine 
residue of 1. However, the orientation of the naphthyl groups in FC131 and 1 are different; the 2-
naphthyl group in FC131 is oriented towards TM5, while the 1-naphthyl group in 1 is facing 
TM2. 
AMD-compound Series. Based on site-directed mutagenesis studies of CXCR4 and binding site 
transfer to CXCR3, the critical CXCR4 receptor residues for binding of the bicyclam AMD3100 
(Figure 1) have been shown to be Asp171, Asp262, and Glu288.36, 37 Based on the fact that AMD3100 
and 1 inhibit binding of the same set of monoclonal antibodies, directed against the extracellular 
loops of CXCR4, it has been suggested that they have similar binding sites and molecular mode 
of action.28, 65 As Asp171, Asp262, and indirectly Glu288 are also involved in binding of 1 (Figure 6), 
the present study confirms that these two compounds bind to the same receptor region.  
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In addition to the key interactions seen for AMD3100, the monocyclam analog AMD3465 
(Figure 3) has been shown to interact with His113 in TM3 and His281 in TM7,39, 40 which were also 
identified as important for 1 in the present study. The reduced potency observed for 1 in the 
D262N and H281A mutants are of particular interest as the same mutations were shown to have 
selective importance for the receptor interactions of AMD3465,39 which contains the same 
(pyridin-2-ylmethyl)amino moiety as 1. Thus, in addition to the key interactions with His113 and 
Asp171 (R2 guanidino group) and Asp262 (R1 amino group), the present study suggests that the 
pyridine ring in the R1 side chain of 1 picks up an additional interaction with His281 in TM7, in 
the same way as AMD3465. 
The interaction pattern for the non-cyclam 4 (Figure 1F) is more unclear, but it has been 
suggested that it binds in a similar fashion as AMD3100 and AMD3465; however, Asp97 and 
Asp171 appeared to have a unique importance for the binding of this analog.40, 66 
 
CONCLUSIONS 
The present study describes the binding of the prototype tripeptidomimetic antagonist 1 to 
CXCR4 based on SAR studies, receptor mapping, and molecular docking. This ternary approach 
resulted in the identification of a binding model for 1 in which the secondary amino group is 
anchored by interaction with Asp262 in TM6, with the distal pyridine ring further involved in a π-
π stacking interaction with His281 in TM7; the Arg-guanidino group engages in polar interactions 
mainly with His113 in TM3 and Asp171 in TM4, while the naphthyl group is tightly packed in a 
hydrophobic subpocket formed by residues Trp94, Tyr45 and Tyr116. Our findings contradict earlier 
suggestions that 1 mimics the binding of the Arg1-Arg1-2-Nal3 fragment in the cyclopentapeptide 
antagonist FC131. Instead, we propose a “hybrid” binding mode for 1 where the guanidino group 
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of the central arginine residue (R2 side chain) overlaps with the binding mode of the Arg2 residue 
in the peptide antagonist FC131 and 2, while the (pyridin-2-ylmethyl)amino moiety (R1 side 
chain) overlaps with the binding mode for the same moiety in the monocyclam AMD3465. This 
experimentally verified binding model for 1 provides important insight for future structure-based 
design of small-molecule CXCR4 antagonists. 
 
EXPERIMENTAL SECTION 
Chemistry. General. All reagents and solvents were purchased from Sigma-Aldrich and used 
as received. 1H and 13C NMR spectra were recorded on a 400 MHz Varian spectrometer. 
Chemical shifts are expressed in ppm relative methanol (1H 3.31 ppm, 13C 49.0 ppm). Coupling 
constants are given in Hertz (Hz). Mass spectra were recorded on a Micromass Quattro LC 
(Micromass, Manchester, UK) and high-resolution mass spectra were recorded on an LTQ 
Orbitrap XL (Thermo Scientific, Bremen, Germany) using positive-mode ESI. Preparative RP-
HPLC was performed on a Waters 600 Semi Prep System equipped with an XBridge™ C18 
column (250 mm × 19 mm, 10 µm particle size) using 15 mL/min flow rate or a Waters 2695 
system equipped with an XBridge™ C18 column (250 mm × 10 mm, 5 µm particle size) using 10 
mL/min flow rate with mixtures of acetonitrile and water (both containing 0.1% TFA) as the 
eluent in both cases Analytical RP-HPLC was performed on a Waters 2695 system equipped 
with an XBridge™ C18 column (250 mm × 4.6 mm, 5 µm particle size,) using 1 mL/min flow 
rate with detection at 214 nm and 254 nm facilitated by a PDA detector (210 – 310 nm). In some 
cases, analyses were performed on a Waters ACQUITY UHPLC H-Class equipped with a 
Waters ACQUITY UHPLC BEH C18 column (1 × 150 mm, 1.75 µm particle size) with a 0.120 
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mL/min flow rate. All compounds undergoing biological evaluation were found to be of >95% 
purity as judged by analytical RP-HPLC with PDA detection (210 – 310 nm). 
N-((S)-5-guanidino-1-(((S)-1-(naphthalen-1-yl)ethyl)amino)-1-oxopentan-2-yl)-4-
(((pyridin-2-ylmethyl)amino)methyl)benzamide (1). The title compound was prepared 
following an earlier reported procedure.29 Purification by RP-HPLC afforded after lyophilization 
the title compound as a white fluffy material. 1H NMR (400 MHz, CD3OD) δ 8.12 (d, J = 8.3, 
1H), 7.96 (d, J = 8.0, 2H), 7.91 – 7.85 (m, 2H), 7.81 (d, J = 8.2, 1H), 7.64 (d, J = 8.0, 2H), 7.60 – 
7.37 (m, 7H), 5.94 – 5.82 (m, 1H), 4.62 (app t, J = 8.0, 1H), 4.41 (s, 2H), 4.39 (s, 2H), 3.19 – 
3.05 (m, 2H), 1.94 – 1.74 (m, 2H), 1.66 (d, J = 6.9, 3H), 1.64 – 1.50 (m, 2H); 13C NMR (100 
MHz, CD3OD) δ 172.7, 169.2, 158.5, 152.3, 150.6, 140.1, 138.8, 136.3, 136.1, 135.4, 132.2, 
131.2, 129.9, 129.3, 129.0, 127.2, 126.7, 126.4, 125.1, 124.1, 124.1, 123.7, 54.9, 51.5, 51.3, 46.2, 
41.9, 30.5, 26.4, 21.2; HRMS (ESI): m/z [M + H]+ calcd for C32H38N7O2: 552.3081, found 
552.3081. The purity of the title compound was found to be >99% using analytical RP-HPLC 
(diode array detection, 210 nm – 310 nm). 
4-(aminomethyl)-N-((S)-5-guanidino-1-(((S)-1-(naphthalen-1-yl)ethyl)amino)-1-
oxopentan-2-yl)benzamide (6). The title compound was prepared adopting a literature 
procedure29 where N-Boc 4-(methylamino)benzoic acid was used instead of 11 (Scheme 1). 
Purification by RP-HPLC afforded after lyophilization the title compound as a white fluffy 
material. 1H NMR (400 MHz, CD3OD) δ 7.89 (d, J = 8.3, 1H), 7.72 (d, J = 8.3, 2H), 7.66 (app t, 
J = 8.2, 1H), 7.58 (d, J = 8.2, 1H), 7.41 – 7.23 (m, 6H), 5.69 – 5.60 (m, 1H), 4.41 (app dd, J = 
8.3, 6.0, 1H), 3.98 (s, 2H), 3.00 – 2.82 (m, 2H), 1.76 – 1.55 (m, 2H), 1.52 – 1.45 (m, 1H), 1.44 
(d, J = 6.9, 3H), 1.40 – 1.30 (m, 1H); 13C NMR (100 MHz, CD3OD) δ 172.7, 169.1, 158.3, 
139.9, 138.0, 135.6, 135.2, 132.0, 129.8, 129.7, 129.1, 128.9, 127.1, 126.6, 126.2, 123.9, 123.5, 
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54.8, 46.0, 43.6, 41.7, 30.3, 26.3, 21.1; HRMS (ESI) : m/z [M + H]+ calcd for C26H33N6O2: 
461.2660, found 461.2664. The purity of the title compound was found to be >99% using 
analytical RP-HPLC (diode array detection, 210 nm – 310 nm). 
4-((benzylamino)methyl)-N-((S)-5-guanidino-1-(((S)-1-(naphthalen-1-yl)ethyl)amino)-1-
oxopentan-2-yl)benzamide (5). A solution of 6 (crude product following TFA mediated 
deprotection, 0.09 mmol) in DMF (2.0 mL) was cooled to 0 °C and K2CO3 (24 mg, 0.18 mmol) 
was added. To this suspension, benzyl bromide (10 µL, 0.09 mmol) was added slowly, and the 
reaction mixture was allowed to stir at rt for 24 h. Water (1 mL) was added and the mixture was 
extracted with diethyl ether (10 mL), washed with water (2 x 5 mL) and a saturated solution of 
NaCl (10 mL). The organic layer was dried over anhydrous MgSO4, filtered and the solvents 
were removed under reduced pressure. The crude product was purified using RP-HPLC followed 
by lyophilization to give the title compound as a fluffy white material. 1H NMR (400 MHz, 
CD3OD) δ 8.12 (d, J = 8.2, 1H), 7.95 (d, J = 8.2, 2H), 7.90 (d, J = 7.8, 1H), 7.81 (d, J = 8.2, 1H), 
7.60 (t, J = 7.6, 3H), 7.57 – 7.45 (m, 8H), 5.95 – 5.82 (m, 1H), 4.62 (app dd, J = 7.9, 6.3, 1H), 
4.33 (s, 2H), 4.28 (s, 2H), 3.21 – 3.06 (m, 2H), 1.97 – 1.73 (m, 2H), 1.66 (d, J = 6.9, 3H), 1.64 – 
1.48 (m, 2H); 13C NMR (100 MHz, CD3OD) 173.0, 169.5, 158.7, 140.3, 136.5, 136.3, 135.7, 
132.5, 132.4, 131.4, 131.3, 131.0, 130.6, 130.1, 129.6, 129.3, 127.5, 127.0, 126.6, 124.3, 123.9, 
55.2, 52.5, 51.7, 46.5, 42.1, 30.7; HRMS (ESI): m/z [M + H]+ calcd for C33H39N6O2: 551.3129, 
found 551.3131. The purity of the title compound was found to be >99% using analytical RP-
HPLC (diode array detection, 210 nm – 310 nm). 
N-((S)-5-guanidino-1-(((S)-1-(naphthalen-1-yl)ethyl)amino)-1-oxopentan-2-yl)-4-
methylbenzamide (7). The title compound was prepared adopting a literature procedure29 where 
4-methylbenzoic acid was used instead of 11 (Scheme 1). Purification by RP-HPLC afforded 
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after lyophilization the title compound as a white fluffy material. 1H NMR (400 MHz, CD3OD) δ 
8.12 (d, J = 8.3, 1H), 7.90 (d, J = 7.7, 1H), 7.81 (d, J = 8.2, 1H), 7.76 (d, J = 8.2, 2H), 7.60 – 
7.45 (m, 4H), 7.30 (d, J = 8.2, 2H), 5.88 (m, 1H), 4.70 – 4.59 (m, 1H), 3.20 – 3.04 (m, 2H), 2.41 
(s, 3H), 1.93 – 1.72 (m, 2H), 1.66 (d, J = 6.9, 3H), 1.64 – 1.48 (m, 2H); 13C NMR (100 MHz, 
CDCl3) 171.5, 168.9, 157.0, 143.1, 138.7, 133.8, 130.5, 129.8, 129.4, 128.9, 128.0, 127.2, 126.3, 
125.8, 125.4, 122.6, 122.4, 53.2, 45.5, 40.4, 29.6, 24.5, 21.4, 21.1; HRMS (ESI): m/z [M + H]+ 
calcd for C26H32N5O2: 446.2551, found 446.2550. The purity of the title compound was found to 
be >99% using analytical RP-HPLC (diode array detection, 210 nm – 310 nm). 
N-((S)-1-(((S)-1-(naphthalen-1-yl)ethyl)amino)-1-oxo-5-ureidopentan-2-yl)-4-(((pyridin-2-
ylmethyl)amino)methyl)benzamide (8). The title compound was prepared adopting a literature 
procedure29 where Fmoc-Cit-OH was used instead of Fmoc-Arg(Pbf)-OH. Purification by RP-
HPLC afforded after lyophilization the title compound as a white fluffy material. 1H NMR (400 
MHz, CD3OD) δ 8.38 (d, J = 4.3, 1H), 7.81 (d, J = 8.3, 1H), 7.67 (d, J = 8.3, 2H), 7.63 – 7.57 
(m, 2H), 7.51 (d, J = 8.2, 1H), 7.32 (m, 3H), 7.27 – 7.13 (m, 5H), 5.56 (app q, J = 6.8, 1H), 4.37 
(app dd, J = 8.7, 5.6, 1H), 4.12 (s, 2H), 4.09 (s, 2H), 2.89 – 2.73 (m, 2H), 1.65 – 1.43 (m, 2H), 
1.36 (d, J = 6.9, 3H), 1.34 – 1.16 (m, 2H); 13C NMR (100 MHz, CD3OD) δ 173.3, 169.3, 162.3, 
152.1, 150.4, 140.2, 139.1, 136.3, 135.9, 135.4, 132.1, 131.2, 129.9, 129.4, 129.0, 127.3, 126.7, 
126.4, 125.2, 124.4, 124.1, 123.6, 55.2, 51.5, 51.2, 46.3, 40.4, 30.5, 27.7, 21.4; HRMS (ESI): m/z 
[M + H]+ calcd for C32H37N6O3: 553.2922, found 553.2921. The purity of the title compound was 
found to be >99% using analytical RP-HPLC (diode array detection, 210 nm – 310 nm). 
(S)-N-(1-(ethylamino)-5-guanidino-1-oxopentan-2-yl)-4-(((pyridin-2-
ylmethyl)amino)methyl)benzamide (9). The title compound was prepared adopting a literature 
procedure29 where ethanamine was used instead of (S)-1-(naphthalene-1-yl)ethanamine. 
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Purification by RP-HPLC afforded after lyophilization the title compound as a white fluffy 
material. 1H NMR (400 MHz, CD3OD) δ 8.66 (d, J = 4.8, 1H), 7.97 (d, J = 8.2, 2H), 7.87 (td, J = 
7.7, 1.7, 1H), 7.64 (d, J = 8.2, 2H), 7.46 – 7.39 (m, 2H), 4.55 (dd, J = 8.6, 5.9 Hz, 1H), 4.40 (s, 
2H), 4.39 (s, 2H), 3.29 – 3.19 (m, 4H), 1.97 – 1.61 (m, 4H), 1.14 (t, J = 7.3, 3H); 13C NMR (100 
MHz, CD3OD) δ 173.6, 169.3, 158.8, 152.3, 150.7, 138.8, 136.3, 136.1, 131.2, 129.4, 125.1, 
124.2, 55.0, 51.5, 51.3, 42.0, 35.4, 30.4, 26.5, 14.8; HRMS (ESI): m/z [M + H]+ calcd for 
C22H32N7O2: 426.2612, found 426.2611. The purity of the title compound was found to be >99% 
using analytical RP-HPLC (diode array detection, 210 nm – 310 nm). 
Biology. Materials. The human CXCR4 receptor cDNA was kindly provided by Tim Wells 
(GSK, UK). The human chemokine CXCL12 was purchased from Peprotech (NJ, USA). The 
monoclonal antibody 12G5 was kindly provided by Jim Hoxie (University of Pennsylvania, 
Philadelphia, PA, USA), and the promiscuous chimeric G protein GαΔ6qi4myr (abbreviated 
Gαqi4myr) was kindly provided by Evi Kostenis (University of Bonn, Germany)67. Myo[3H]inositol 
(PT6-271), scintillation proximity assay (SPA) beads, and Bolton-Hunter reagent for 12G5 
iodination (in-house procedure)37 were purchased from Perkin Elmer (MA, USA). Primer-
cDNAs for mutagenesis were purchased from TAG Copenhagen (Copenhagen, Denmark), and 
AG1-X8 anion exchange resin from Bio-Rad (CA, USA). Stock solutions of the ligand 
antagonists were prepared in different mixtures of DMSO:water, and dilutions were made in 
water. For dilutions of CXCL12, a buffer with 1 mM acetic acid + 0.1% BSA was used. 
Site-directed Mutagenesis. Point mutations were introduced in the receptor by the polymerase 
chain reaction overlap extension technique68 or the QuikChangeTM technique (Agilent 
Technologies, CA, USA), using WT-CXCR4 as a template. All reactions were carried out using 
Pfu polymerase (Stratagene, CA, USA) under conditions recommended by the manufacturer. The 
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mutations were cloned into the eukaryotic expression vector pcDNA3.1+ (Invitrogen, UK), and 
were verified by restriction endonuclease digestion and DNA sequencing (Eurofins MWG 
Operon, Germany). 
Transfections and Tissue Culture. COS-7 cells were grown at 10% CO2 and 37 °C in 
Dulbecco's modified Eagle's medium with glutamax (Invitrogen, U.K.) adjusted with 10% fetal 
bovine serum, 180 units/mL penicillin, and 45 μg/mL penicillin/streptomycin (PenStrep). 
Transfection of the COS-7 cells was performed by the calcium phosphate precipitation method.69 
Phosphatidylinositol (PI) Turnover Assays. Transfection of COS-7 cells was carried out 
according to the abovementioned procedure. Shortly, 6 × 106 cells were transfected with 20 μg of 
receptor cDNA along with 30 μg of the promiscuous chimeric G protein, Gαqi4myr, which turns 
the Gαi-coupled signal, the most common pathway for endogenous chemokine receptors, into the 
Gαq pathway (phospholipase C activation measured as IP3 turnover). Two alternative methods, 
which were found to give the same result, were used:  
Anion-exchange Separation of Phosphoinositides. In the classic IP3-assay which includes an 
anion-exchange chromatography step, one day after transfection COS-7 cells (1.5 × 105 
cells/well) were incubated for 24 h with 2 μCi of myo[3H]inositol in 0.3 mL of growth medium 
per well in a 24-well plate. Next day, the cells were washed twice in PBS, and were incubated 
(90 min) in 0.2 mL of Hank's balanced salt solution (Invitrogen, U.K.) supplemented with 10 
mM LiCl at 37 °C in the presence of various concentrations of the tested compounds. Cells were 
then extracted by addition of 1 mL of 10 mM formic acid to each well followed by incubation on 
ice for 30−60 min. The generated [3H]inositol phosphates were purified on an AG 1-X8 anion 
exchange resin. Following the addition of multipurpose liquid scintillation cocktail (Gold Star, 
Triskem-International, France), γ-radiation was counted in a Beckman Coulter counter LS6500.  
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Scintillation Proximity Assay. The day after transfection, COS-7 cells (35 000 cells/well) were 
incubated for 24 h with 0.5 μCi/mL myo[3H]inositol in 100 μL of growth medium per well in a 
96-well plate. The following day, cells were treated as mentioned in the classic assay with 
volumes adjusted as follows: 100 μL of reaction solution with LiCl, and 50 μL of ice cold formic 
acid. Next, the generated [3H]inositol phosphates were quantified by radioactivity measurement; 
in brief, 20 μL of the formic acid cell extracts were transferred to a white 96-well plate, and 80 
μL of 1:8 diluted YSi poly-D-lysine coated beads (SPA-beads, PerkinElmer, MA, USA) was 
added. Plates were sealed, agitated at maximum speed for at least 30 min, and centrifuged (5 min 
at 1500 rpm) before γ-radiation was counted in a Packard Top Count NXT counter. In both 
assays, determinations were made in duplicate.  
Binding Experiments. 6 × 106 COS-7 cells were transfected with 40 μg of receptor cDNA and 
transferred to culture plates. The number of cells seeded per well was determined by the apparent 
expression efficiency of the receptors and was aimed at obtaining 5−10% specific binding of the 
added radioactive ligand. Two days after transfection, cells were assayed by competition binding 
for 3 h at 4 °C using 10−15 pM 125I-12G5 plus unlabeled ligand in 0.2 ml of 50 mM Hepes 
buffer, pH 7.4, supplemented with 1 mM CaCl2, 5 mM MgCl2, and 0.5% (w/v) bovine serum 
albumin. Following incubation, cells were washed quickly two times in 4 °C binding buffer 
supplemented with 0.5 M NaCl (and on ice). Cells were lysed by addition of 0.5 ml carbamide 
solution (18% acetic acid, 8M urea, 2% v/v P-40) and radioactivity was counted in Beckman 
Coulter counter LS6500. Nonspecific binding was determined in the presence of 0.1 μM 
unlabeled 12G5. Determinations were made in duplicates. 
Cell Surface Expression Measurement (ELISA). COS-7 cells were transfected with FLAG-
tagged receptor DNA in 96-well plates (6 × 103 cells/well). Following the transfection (48 
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hours), cells were washed 3 times in Tris-buffered saline (TBS), fixed in 3.7% formaldehyde for 
15 min at rt, washed and incubated in blocking solution (TBS with 2% BSA) for 30 min. Cells 
were incubated for 2 hours with anti-FLAG (M1) antibody (Sigma-Adrich) at 2 µg/mL in TBS 
with 1mM CaCl2 and 1% BSA. After three washes with TBS/CaCl2/BSA the cells were 
incubated with goat anti-mouse horseradish peroxidase (HRP)-conjugated antibody at 0.8 µg/mL 
(Thermo Fischer Scientific, MA, USA) for 1 hour. After 3 washes, the immunoreactivity was 
revealed by the addition of TMB Plus substrate (Kem-En-Tec, Taastrup, Denmark) and the 
reaction was stopped with 0.2 M H2SO4. Absorbance was measured at 450 nm on a Wallac 
platereader (Perkin Elmer). 
Statistical Calculations. The apparent EC50 and IC50 values were determined by nonlinear 
regression using the GraphPad Prism 4 software (GraphPad Software, San Diego, CA). P-values 
were calculated using unpaired two-tailed t-test with 95% confidence intervals. The data analysis 
was performed as recently described.35  
Computational Modeling Procedure. All molecular modeling calculations were performed 
using the Schrödinger software suite 2012.70 Default settings were used, if not specified 
otherwise. The crystal structure of CXCR4 in complex with 2 (PDB-code: 3OE0)33 was first 
prepared and optimized with the Protein Preparation Wizard workflow71 using the same 
procedure as previously described.23 The automatically assigned tautomeric and protonation 
states (pH 7.4) for ionizable residues were kept, except for Asp262, which was manually assigned 
a negative charge (predicted to be neutral). The ligand (1) was docked to the prepared receptor 
structure using the induced-fit workflow54 with a docking box of (26 Å)3 centered on Asp187. The 
ligand was built with two positive charges (the guanidino group and the amino group), and the 
“penalize nonplanar conformation” option was chosen for amide bonds.  
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In the first step (Glide docking: flexible ligand, rigid receptor), 50 poses were generated using 
a softened van der Waals potential (scaling 0.5) for both receptor and ligand. In the second step 
(Prime refinement: rigid ligand, flexible receptor), receptor residues within a radius of 5.0 Å 
from the ligand were optimized for the 50 initial poses. In the final step (Glide redocking: 
flexible ligand, rigid receptor), the ligand was redocked into the optimized binding site using the 
extra precision (XP) scoring function, and the top 20 poses within an energy window of 30 
kcal/mol were kept. In the absence of constraints, a number of irrelevant poses were generated, 
and a H-bond constraint (applied in both docking steps) was therefore assigned to the Nδ1 atom 
of His113, which resulted in the identification of the binding mode for 1 that is shown in Figure 6. 
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ABBREVIATIONS 
2-Nal, L-3-(2-naphthyl)alanine; CXCL12, CXC chemokine ligand 12; CXCR4, CXC 
chemokine receptor 4; DIPEA, N,N-diisopropylethylamine; ECL, extracellular loop; EDCI, N-
(3-dimethylaminopropyl)-N′-ethylcarbodiimide; HOBt, 1-hydroxybenzotriazole; Pbf, 2,2,4,6,7-
pentamethyl-2,3-dihydrobenzofuran-5-sulfonyl; PI, phosphatidylinositol; PyBOP, (benzotriazol-
1-yloxy)tripyrrolidinophosphonium hexafluorophosphate; SPA, scintillation proximity assay; 
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